C4-2 Xenograft Model Service for Prostate Cancer

The C4-2 cell line provides a sophisticated and highly relevant in vivo platform for investigating castration-resistant prostate cancer (CRPC) and the progression of metastatic disease. As a specialized pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision C4-2 Xenograft Model Service, meticulously optimized to provide reproducible, audit-ready data packages that accelerate your prostate cancer drug discovery and development pipeline.

Overview of C4-2 Xenograft Model for Prostate Cancer

The C4-2 xenograft model is an advanced in vivo translational system widely utilized in oncology research for the study of metastatic castration-resistant prostate cancer. Derived from the LNCaP cell line through serial passage in castrated male nude mice, C4-2 cells exhibit a unique ability to grow in androgen-depleted environments while maintaining the expression of functional androgen receptors and prostate-specific antigen (PSA).

Biologically, the C4-2 model is distinguished by its enhanced metastatic potential, particularly its capacity to form bone metastases, which closely mimics the clinical progression of human prostate cancer. This model retains essential phenotypic features of CRPC, including autonomous growth, resistance to androgen deprivation therapy, and complex signaling network responses to emerging therapeutic agents. Consequently, the C4-2 model is extensively deployed in pre-clinical screening programs to assess the anti-tumor and anti-metastatic potency of novel small-molecule inhibitors, hormonal therapies, and combination treatment regimens in a physiologically relevant in vivo setting.

Fig 1. PET-data-based time-activity curves of [18F]F-siPSMA-14 accumulation in tumor xenografts of the HET-CAM model (left) and the mouse model (right). (Löffler J, et al., 2021)

Cell Line Information: C4-2

The C4-2 cell line is a subline of LNCaP, evolved to thrive in androgen-independent conditions. These cells are characterized by their aggressive growth and metastatic properties in vitro, making them a critical tool for pre-clinical research into advanced prostate cancer.

Our Services

Workflow of C4-2 Xenograft Model Construction

• Cell Culture & Quality Control: Human C4-2 cells are expanded in vitro using certified nutrient media under optimized physiological conditions. STR authentication and mycoplasma screening are performed prior to inoculation to ensure absolute genetic integrity and purity.
• Host Selection & Preparation: Immunodeficient rodent models are utilized for tumor engraftment, with all animals maintained in a controlled, pathogen-free environment to ensure physiological stability and consistency throughout the study.
• Precision Inoculation: A calibrated suspension of high-viability C4-2 cells is prepared, often supplemented with an extracellular matrix (e.g., Matrigel) to optimize take efficiency. Cells are inoculated in vivo via subcutaneous or orthotopic injection into the host to facilitate the development of a measurable, solid tumor.
• Longitudinal Monitoring: Tumor size is measured systematically using digital calipers to monitor volume progression. Animal health, activity, and body weight are recorded periodically to document systemic tolerance and clinical status.
• Randomization & Treatment: Once solid tumors reach a predefined, statistically significant volume, animals are randomized into matched cohorts to ensure baseline parity before the initiation of customized therapeutic dosing regimens.

Fig 2. C4-2 Xenograft Model Construction Workflow

Case Study - C4-2 Xenograft Model Development

A pre-clinical validation study was conducted using the C4-2 xenograft model to evaluate the therapeutic efficacy of a novel inhibitor targeting the androgen receptor signaling axis. Following the successful subcutaneous inoculation of C4-2 cells into immunodeficient mice, the host animals developed firm, rapidly expanding solid tumors. The treatment group demonstrated a clear, statistically significant inhibition of tumor growth compared to the vehicle-treated control group, confirming the model's high sensitivity and predictive reliability for screening novel interventions against advanced prostate cancer.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in managing specialized prostate cancer lineages, providing highly reproducible in vivo translational platforms for complex hormonal-resistance research.
• Rigorous Quality Control: Meticulous cell validation and standardized operating procedures that minimize experimental variability across all project stages.
• Tailored Experimental Design: Highly flexible protocols that adapt to specific animal strain requirements, custom dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready report providing comprehensive tumor growth metrics and statistical validations.

Contact us

Accelerating your prostate cancer drug pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our C4-2 platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.